NEW YORK – Metabolomics firm Numares said Thursday that it has signed an agreement with Bruker to bring nuclear magnetic resonance-based diagnostics to market.
The collaboration aims to transition Regensburg, Germany-based Numares' Axinon platform, which combines NMR measures of metabolites with AI analysis, from research to routine clinical use.